livingevidence.org.au Open in urlscan Pro
141.193.213.21  Public Scan

Form analysis
0 forms found in the DOM

Text Content

This is the hover veil
Menu Menu

 * Home
 * About Us
 * About LEAPP
 * About living evidence
 * Living guidelines
 * Resources
 * News
 * Contact us
 * 

 * About Us
 * About LEAPP
 * About living evidence
 * Living guidelines
 * Resources
 * News
 * Contact us





CARING FOR PEOPLE WITH COVID-19


SUPPORTING AUSTRALIA’S HEALTHCARE PROFESSIONALS WITH CONTINUALLY UPDATED,
EVIDENCE-BASED CLINICAL GUIDELINES

Funding has now been discontinued for the National Clinical Evidence Taskforce
and the COVID-19 guidelines as of 30 June 2023.

These guidelines are no longer continually updated but will remain online until
the guidance becomes inaccurate and/or no longer reflects the evidence or
recommended practice.

For three years, the COVID-19 guideline delivered trusted, up-to-date clinical
guidelines and flowcharts for everyone throughout the COVID-19 pandemic.

The Taskforce provided a successful model of rapid evidence surveillance, while
implementing a world-first, cross-disciplinary collaboration, including
healthcare workers, evidence experts, consumers and 35 peak health bodies across
Australia.

Communiques

Living
Guidelines
Clinical Flowcharts



LIVING
GUIDELINES



Evidence-based clinical COVID-19 guidelines updated with the latest research

WE HAVE DEVELOPED RECOMMENDATIONS THAT COVER:

 * Consumer-centered care in the context of COVID-19
 * Definition of disease severity
   * Definition of disease severity for adults
   * Definition for disease severity for children and adolescents
 * Monitoring and markers of clinical deterioration
   * Monitoring and markers of clinical deterioration
   * Pulse oximeters
     * Pulse oximeters for adults
     * Pulse oximeters for children and adolescents
 * Care after COVID-19
   * Goals of care
   * Assessment and diagnosis in patients with continuing symptoms after
     COVID-19
   * Management in patients with continuing symptoms after COVID-19
   * Therapies not recommended outside of clinical trials
 * Drug treatments
   * Recommended drug treatments
     * Casirivimab plus imdevimab (Ronapreve)
       * Casirivimab plus imdevimab (Ronapreve) for adults
       * Casirivimab plus imdevimab (Ronapreve) for pregnant or breastfeeding
         women
       * Casirivimab plus imdevimab (Ronapreve) for children and adolescents
     * Corticosteroids (inhaled)
       * Corticosteroids (inhaled) for adults
       * Corticosteroids (inhaled) for children and adolescents
     * Corticosteroids (systemic)
       * Corticosteroids (systemic) for adults
       * Corticosteroids (systemic) for pregnant or breastfeeding women
       * Corticosteroids (systemic) for children or adolescents
     * Molnupiravir (Lagevrio)
       * Molnupiravir (Lagevrio) for adults
       * Molnupiravir (Lagevrio) for pregnant or breastfeeding women
       * Molnupiravir (Lagevrio) for children and adolescents
     * Nirmatrelvir plus ritonavir (Paxlovid)
       * Nirmatrelvir plus ritonavir (Paxlovid) for adults
       * Nirmatrelvir plus ritonavir (Paxlovid) for pregnant or breastfeeding
         women
       * Nirmatrelvir plus ritonavir (Paxlovid) for children and adolescents
     * Other immunomodulating drugs
       * Abatacept
       * Baracitinib
       * Infliximab
       * Sarilumab
       * Tocilizumab
     * Regdanvimab (Regkirona)
       * Regdanvimab (Regkirona) for adults
       * Regdanvimab (Regkirona) for pregnant or breastfeeding women
       * Regdanvimab (Regkirona) for children and adolescents
     * Remdesivir
       * Remdesivir for adults
       * Remdesivir for pregnant or breastfeeding women
       * Remdesivir for children and adolescents
     * Sotrovimab
       * Sotrovimab for adults
       * Sotrovimab for pregnant women
       * Sotrovimab for children and adolescents
     * Tixagevimab plus cilgavimab (Evusheld)
       * Tixagevimab plus cilgavimab (Evusheld) for adults
       * Tixagevimab plus cilgavimab (Evusheld) for pregnant or breastfeeding
         women
       * Tixagevimab plus cilgavimab (Evusheld) for children and adolescents
   * Drug treatments that are not recommended
     * Aspirin
     * Azithromycin
     * Colchicine
     * Convalescent plasma
     * Favipiravir
     * Hydroxychloroquine
     * Hydroxychloroquine plus azithromycin
     * Interferon β-1a
     * Interferon β-1a plus lopinavir-ritonavir
     * Ivermectin
     * Lopinavir-ritonavir
     * Sodium-glucose transport protein 2 inhibitors
   * Drug treatments not recommended outside of clinical trials
     * Antiandrogens
       * Dutasteride
     * Antineoplastics
       * Angiotensin 2 receptor agonist (C21)
       * Camostat mesilate
       * Opaganib
     * Antiparasitic, antifungals and other anti-infective agents
       * Chloroquine
       * Doxycycline
       * Ivermectin plus doxycycline
       * Nitazoxanide
     * Antihypertensives
       * Telmisartan
     * Antithrombotic, antiplatelets and related therapies
       * Sulodexide
     * Antivirals
       * Baloxavir marboxil
       * Darunavir-cobicistat
       * Enisamium
       * Ensovibep
       * Sofosburiv-daclatasvir
       * Triazavirin
       * Umifenovir
     * Human and blood derived products
       * Human umbilical cord mesenchymal stem cells
       * Intravenous immunoglobulin
       * Intravenous immunoglobulin plus methylprednisolone
     * Immunomodulating drugs
       * Anakinra
       * CD24Fc
       * Lenzilumab
       * Ruxolitinib
       * Tofacitinib
     * Interferons
       * Interferon β-1a (inhaled)
       * Interferon β-1b
       * Interferon gamma
       * Interferon kappa plus trefoil factor 2 (IFN-κ plus TFF2)
       * Peginterferon lambda
     * Other antibody related therapies
       * Bamlanivimab
       * Bamlanivimab plus etesevimab
       * Bebtelovimab
       * Regdanvimab
     * Other therapies
       * Almitrine
       * Aprepitant
       * Bromhexine hydrochloride
       * Fluvoxamine
       * Recombinant human granulocyte colony-stimulating factor (rhG-CSF)
       * Sabizabulin
     * Vitamins, supplements and cofactors
       * Combined metabolic cofactor supplementation (CMCS)
       * N-acetylcysteine
       * Vitamin C
       * Vitamin D analogues (calcifediol/cholecalciferol)
       * Zinc
     * Other drug treatments
   * Drug treatments under review
   * Drug treatments not currently under review
 * Chemoprophylaxis
   * Casirivimab plus imdevimab (Ronapreve) for post-exposure prophylaxis
   * Hydroxychloroquine for pre-exposure prophylaxis
   * Hydroxychloroquine for post-exposure prophylaxis
   * Tixagevimab plus cilgavimab (Evusheld) for pre-exposure prophylaxis
   * Tixagevimab plus cilgavimab (Evusheld) for post-exposure prophylaxis
 * Respiratory support in adults
   * Requiring non-invasive respiratory support
     * High-flow nasal oxygen and non-invasive ventilation
     * Prone positioning (non-invasive)
     * Respiratory management of the deteriorating child
   * Requiring invasive mechanical ventilation
     * Prone positioning (mechanical ventilation)
     * Positive end-expiratory pressure (PEEP)
     * Recruitment manoeuvres
     * Neuromuscular blockers
     * High-frequency oscillatory ventilation (HFOV)
     * Videolaryngoscopy
     * Extracorporeal membrane oxygenation (ECMO)
 * Venous thromboembolism (VTE) prophylaxis
   * VTE prophylaxis for adults
   * VTE prophylaxis for pregnant and postpartum women
   * VTE prophylaxis for children and adolescents
 * Therapies for existing indications in patients with COVID-19
   * ACEIs/ARBs in patients with COVID-19
   * ACEIs in postpartum women
   * Steroids for people with asthma or COPD with COVID-19
   * Oestrogen-containing therapies
 * Timing of surgery following COVID-19 infection
 * Pregnancy and perinatal care
   * Antenatal corticosteroids
   * Magnesium sulfate
   * Mode of birth
   * Delayed umbilical cord clamping
   * Skin-to-skin contact
   * Breastfeeding
   * Rooming-in
 * Child and adolescent care
   * Paediatric Inflammatory Multisystem Syndrome (PIMS-TS)
     * Aspirin and antithrombotic agents updated
     * Immunomodulatory agents
     * VTE prophylaxis

VIEW ALL EVIDENCE-BASED RECOMMENDATIONS HERE:

 * Australian guidelines for the clinical care of people with COVID-19 (Version
   74.1)



We will revise and add recommendations each week as our evidence teams and
expert panels identify priority clinical questions and synthesise new research.






CLINICAL
FLOWCHARTS



Flowcharts incorporating living guideline recommendations and guidance issued or
endorsed by Taskforce members

RISK CLASSIFICATION

 * Risk classification tool for adults with mild COVID-19

DECISION TOOLS

 * Drug treatments for at risk adults with COVID-19 who do not require oxygen
 * Drug treatments for at risk children and adolescents with COVID-19 who do not
   require oxygen
 * Good practice guide to consumer-centered care for patients with COVID-19

DRUG TREATMENTS

 * Drug treatments for adults with COVID-19
 * Paxlovid prescribing guide
 * Drug treatments for children and adolescents
 * Drug treatments for pregnancy and breastfeeding

PATHWAYS TO CARE

 * Pathways to care for adults with COVID-19
 * Pathways to care for children and adolescents with COVID-19

MANAGEMENT OF COVID-19 AND CARE AFTER COVID-19

 * Management of adults with mild COVID-19
 * Management of adults with moderate to severe COVID-19
 * Management of adults with severe to critical COVID-19
 * Respiratory support for adults with severe to critical COVID-19
 * Care of people after COVID-19

MANAGEMENT OF SPECIAL POPULATIONS

 * Care at home for children and adolescents with mild COVID-19
 * Care in hospital for children and adolescents with mild to moderate COVID-19
 * Care in hospital for children and adolescents with severe to critical
   COVID-19
 * Care for children and adolescents with suspected or confirmed PIMS-TS/MIS-C
 * Management of people with COVID-19 who are older and living with frailty
   and/or cognitive impairment
 * Management of people with COVID-19 who are receiving palliative care

CPR DURING THE PANDEMIC

 * Preparedness for CPR during the COVID-19 pandemic
 * CPR for adults with COVID-19 in healthcare settings
 * Basic Life Support in the community during the COVID-19 pandemic




EXPERT PANELS


 * Expert Clinical Panels
   * Drug Treatment Panel
   * Primary and Chronic Care Panel
   * Acute and Critical Care Panel
   * Pregnancy and Perinatal Care Panel
   * Paediatric and Adolescent Care Panel
   * Care of Older People and Palliative Care Panel
   * Expert Advisory Group
   * Pathways to Care Working Group
   * Cardiac Arrest Working Group
   * In Vitro Working Group
   * COVID-19 Care Working Group
 * Consumer Panel




COVID-19
RESEARCH




FIND COVID-19 STUDIES AROUND THE WORLD

Cochrane’s COVID-19 Study Register is a freely-available, continually-updated,
annotated reference collection of human studies on COVID-19, including
interventional, observational, diagnostic, prognostic, epidemiological, and
economic designs.




FIND COVID-19 STUDIES IN AUSTRALIA

The ANZCTR is an online registry of clinical trials being undertaken in
Australia, New Zealand and elsewhere. A list of coronavirus/COVID-19 studies
currently recruiting in Australia is available here.




CORE OUTCOMES FOR COVID-19 RESEARCH

The COVID-19-COS project is an international initiative bringing together
patients, the public and health professionals to identify, prioritise and agree
on the most important outcomes for research in COVID-19.





ALEC
MEMBERS

Cochrane

Allied Health

AAAPC

AAG

ACEM

ACIPC

ASID

Ascept

ASHM

ANZCA

ANZICS

ANZSGM

ACCCN

ACM

ACN

ACNN

ACRRM

Palliative Care

APNA

ARC

AC Para

Australian Sleep Association

ASA

CENA

CMUS

CRANA

NACCHO

RACP

RACS

RANZCOG

RANZCP

RACGP

RMSANZ

SHPA

TSANZ

THANZ




PARTNERS
AND FUNDERS


   PARTNERS

 * 
 * 
 * 
 * 
 * 

 * 
   
 * © 2024 Australian Living Evidence Collaboration. All rights reserved.
 * Disclaimer
 * Privacy policy